The Technical Analyst
Hikma Pharmaceuticals PLC [HKMPY]
Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Hikma Pharmaceuticals PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $49.02
America/New_York / 2 mai 2024 @ 12:36
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 437.85 mill |
| EPS: | 1.700 |
| P/E: | 28.83 |
| Earnings Date: | Feb 22, 2024 |
| SharesOutstanding: | 110.94 mill |
| Avg Daily Volume: | 0.0001 mill |
| RATING 2024-05-02 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.99x |
| Company: PE 28.83 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.92x |
| Company: PE 28.83 | industry: PE 31.46 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$86.93 (77.35%) $37.91 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 48.71 - 49.33 ( +/- 0.63%) |
| ATR Model: 14 days |
Forecast:
14:16 - $49.02
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $49.02 (0.00% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0001 mill |
| % of Avg. Vol | 175.51 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HKMPY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HKMPY
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Latest Press Releases
2024-02-21 13:20:00 - Press Release
Hikma Hosts White House Drug Policy Director Dr. Rahul Gupta At Its Columbus, Ohio Manufacturing Facility
Continues hikma and the office of national drug control policy effort to combat the opioid overdose epidemic in the us columbus, ohio , feb. 21, 2024 /prnewswire/ -- hikma pharmaceuticals plc (hikma), the multinational pharmaceutical company, today welcomed dr. rahul gupta, director of the white house office of national drug control policy (ondcp), to its columbus, ohio manufacturing facility for a visit and important dialogue on the us opioid overdose epidemic and hikma's and ondcp's shared goal of expanding the availability and awareness of life-saving naloxone. during the visit, dr. gupta met with hikma employees and toured the columbus facility, observing firsthand the production of hikma's overdose reversal medicine kloxxado® (naloxone hcl) nasal spray 8mg.
2024-02-05 07:00:00 - Press Release
Hikma Announces Us Launch Of Combogesic® Iv
Offers health care providers a new multimodal approach to adult pain management london , feb. 5, 2024 /prnewswire/ -- hikma pharmaceuticals plc (hikma), the multinational pharmaceutical company, announces the launch of combogesic® iv (acetaminophen and ibuprofen) injection in the us. combogesic® iv is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (nsaid).
2023-10-03 07:00:00 - Press Release
Hikma Marks Two-year Anniversary Of Kloxxado® Launch By Surpassing 375,000 Doses Donated In The Us
Important milestone in combatting the opioid overdose epidemic london , oct. 3, 2023 /prnewswire/ -- hikma pharmaceuticals plc (hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of kloxxado® (naloxone hcl) nasal spray 8mg in the us – an important milestone in its ongoing work to help combat the opioid overdose epidemic. kloxxado® contains twice as much naloxone per spray as narcan® (naloxone hcl) 4mg nasal spray, in a ready-to- use format to reverse the effects of opioid overdose.1 since launching kloxxado® in 2021, hikma has donated the lifesaving medicine to harm reduction groups, community organizations and others across the us.
2023-08-10 08:28:00 - Press Release
Rakuten Medical And Hikma Sign Exclusive Licensing Agreement For Alluminox™ Platform Cancer Treatment In The Middle East And North Africa
San diego , aug. 10, 2023 /prnewswire/ -- rakuten medical, inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary alluminox™ platform today announces an exclusive licensing and commercialization agreement with hikma pharmaceuticals plc (hikma), a multinational pharmaceutical company for the middle east and north africa (mena). under the terms of the agreement, hikma has an exclusive license to commercialize products in rakuten medical's pipeline using its photoimmunotherapy technology platform, alluminox™, in all its mena markets.
2023-07-26 12:45:00 - Press Release
Hikma Ventures Invests In Octave Bioscience, A Precision Care Platform For Multiple Sclerosis And Other Neurodegenerative Diseases
London , july 26, 2023 /prnewswire/ -- hikma pharmaceuticals plc (hikma), the multinational pharmaceutical company, announces that its venture capital arm, hikma ventures , has invested in octave bioscience , the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (ms). founded by william hagstrom, ceo, and melinda thomas, coo, octave's multimodal precision care solution provides comprehensive, objective, and actionable insights that bring scientific clarity to the patient's disease over time.
Latest News
2024-02-01 12:34:51 - Reuters
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims that they helped fuel the deadly U.S. opioid epidemic.
2024-01-09 03:48:00 - Seeking Alpha
U.K. Dividend Stocks Portfolio: 2023 Year-End Review
2023-11-02 06:26:56 - Proactive Investors
Hikma Pharmaceuticals upgrades guidance for all segments except injectables
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has upgraded its full-year guidance for two out of three of its business segments following “good momentum” in the first half, but lowered annual sales expectations for injectables, it said in a trading update today. Riad Mishlawi, Chief Executive Officer of Hikma, said in a statement today: "The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses.
2023-05-06 05:25:00 - Seeking Alpha
Selling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 Months
Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of progressive dividend growth, so I added it to my dividend portfolio in October 2022.
2023-02-26 13:13:09 - Seeking Alpha
Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Call Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 AM ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Chief Executive Officer Brian Hoffmann - President of Generics Riad Mishlawi - President of Injectables Mazen Darwazah - Vice Chairman of Hikma and Head of the Branded Business Khalid Nabilsi - Chief Financial Officer Guy Featherstone - Associate Director, Investor Relations Conference Call Participants Peter Verdult - Citi Thibault Boutherin - Morgan Stanley Paul Cuddon - Numis Emily Field - Barclays James Gordon - JPMorgan Harry Sephton - Credit Suisse Christian Glennie - Stifel Victoria Lambert - Berenberg Susan Ringdal Good morning everyone, and thank you for joining Hikma's results Q&A today...
2023-01-05 04:32:48 - Proactive Investors
Hikma Pharmaceuticals higher as Citi analysts revise target price
Analysts at Citi have revised their net present value (NPV)-based price target for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to £19.20 with a £28-£11 bull-bear valuation range for the stock. In a note to clients, the analysts said: "Our Deconstructed-Buy-Thesis back in August argued the risk-reward was highly attractive, despite carrying deliberately conservative US Generics forecasts (
2023-01-03 04:11:47 - Proactive Investors
Hikma Pharmaceuticals launches generic version of narcolepsy treatment Xyrem in US
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) said it has launched an authorised generic version of Jazz Pharmaceuticals' Xyrem (sodium oxybate) oral solution CIII. Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat people with narcolepsy for symptoms of sudden onset of weak or paralyzed muscles (cataplexy) and excessive daytime sleepiness (EDS), the multinational pharmaceutical company said in a statement.
2022-08-05 16:34:13 - Seeking Alpha
Hikma Pharmaceuticals Plc (HKMPF) 2022 Interim Results - Earnings Call Transcript
Hikma Pharmaceuticals Plc. (OTCPK:HKMPF) 2022 Interim Results August 4, 2022 5:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants Said Darwazah Hello everyone.
2022-05-24 03:48:44 - Proactive Investors
Hikma Pharmaceuticals loses CEO
The chief executive of Hikma Pharmaceuticals PLC (AIM:HIK, OTC:HKMPF), Siggi Olafsson, has stepped down from the role, with a permanent replacement yet to be found. The British injectable medicine business announced today that Olafsson had resigned from the post and from Hikma's board of directors after four years in the role.
2022-02-24 23:34:06 - Seeking Alpha
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript